Valuation: Axsome Therapeutics, Inc.

Market Cap 12.4B 10.89B 10.13B 9.3B 17.47B 1,194B 17.73B 120B 47B 587B 46.56B 45.55B 2,030B P/E 2026 *
-117x
P/E 2027 * 43.4x
Enterprise Value 12.29B 10.8B 10.04B 9.21B 17.31B 1,184B 17.58B 119B 46.58B 582B 46.14B 45.15B 2,012B EV / Sales 2026 *
12.6x
EV / Sales 2027 * 7.52x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+4.78%
Current month-1.54%
1 month-0.28%
3 months+29.60%
6 months+30.61%
Current year+31.95%
1 week 221.24
Extreme 221.24
244.6
1 month 221.21
Extreme 221.21
252.6
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 11/01/2012
Director of Finance/CFO 51 15/05/2018
Chief Operating Officer 42 31/03/2014
Director TitleAgeSince
Chairman 57 11/01/2012
Director/Board Member 64 30/11/2014
Director/Board Member 58 30/11/2014
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
11/06/26 Sell

Director

-286 0.0006%
10/06/26 Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+4.78%+139.02%+216.27% 12.4B
+0.63%-3.06%+16.50%-10.25% 66.74B
-0.28%+3.07%+37.15%+203.36% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
+1.90%-5.07%-56.99%-56.52% 38.25B
+0.78%-1.84%+53.73%-23.77% 29.85B
+0.84%+0.36%+67.62%+87.37% 23.51B
-5.17%-12.54%+58.33%-55.18% 21.45B
+1.31%+3.24%+81.47%+159.24% 16.47B
+0.81%-0.56%+63.38%+125.02% 16.38B
Average +1.58%-0.17%+51.20%+69.73% 32.65B
Weighted average by Cap. +2.02%+0.19%+36.58%+55.14%

Financials

2026 *2027 *
Net sales 979M 860M 800M 734M 1.38B 94.27B 1.4B 9.49B 3.71B 46.35B 3.67B 3.6B 160B 1.6B 1.4B 1.3B 1.2B 2.25B 154B 2.28B 15.48B 6.05B 75.58B 5.99B 5.86B 261B
Net income -107M -94.24M -87.64M -80.42M -151M -10.33B -153M -1.04B -407M -5.08B -403M -394M -17.56B 309M 271M 252M 232M 435M 29.77B 442M 3B 1.17B 14.64B 1.16B 1.14B 50.6B
Net Debt -111M -97.23M -90.42M -82.97M -156M -10.66B -158M -1.07B -419M -5.24B -416M -407M -18.12B -394M -346M -322M -295M -555M -37.92B -563M -3.82B -1.49B -18.64B -1.48B -1.45B -64.46B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
24/07/26 US$241.00 -0.22% 461,989
23/07/26 US$241.53 +0.80% 500,364
22/07/26 US$239.62 +1.13% 648,276
21/07/26 US$236.95 +6.91% 993,638
20/07/26 US$221.64 -3.63% 776,410
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
241.00USD
Average target price
282.51USD
Spread / Average Target
+17.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock